Agilent to acquire Resolution Bioscience

Create PDF

March 3, 2021—Agilent Technologies announced it has entered into a definitive agreement to acquire Resolution Bioscience, a next-generation-sequencing–based technology company. Agilent will pay $550 million in cash at closing and up to an additional $145 million based on achieving future performance milestones.

Resolution Bioscience’s noninvasive liquid biopsy assay platform supports the biopharma services market and the clinical oncology diagnostic testing market. The platform has been designed for a centralized CLIA test service and a distributable kit format. The company’s homologous recombination deficiency assay received breakthrough device designation from the FDA.